Life Sciences Voice

Life Sciences Voice Life Sciences Voice is the leading resource for life sciences executives to get crucial insights

Life Sciences Voice is the leading resource for life sciences executives to get crucial insights, explore the latest innovations, and learn about industry trends. Life Sciences Voice provides the community with thought-provoking commentary in multiple formats covering a range of issues from drug discovery to commercial success.

The future of pharmaceutical commercial excellence starts here. Join senior leaders from Sanofi, Novo Nordisk, Takeda, M...
09/23/2026

The future of pharmaceutical commercial excellence starts here. Join senior leaders from Sanofi, Novo Nordisk, Takeda, Merck, GSK, AstraZeneca, Johnson & Johnson and more at Future Pharma Europe on 20–21 October 2026 in Amsterdam.

Discover practical strategies for AI, omnichannel HCP engagement, CRM transformation and commercial excellence through interactive workshops, real-world case studies and peer networking.

Register now and get 10% off: https://tinyurl.com/bdh3nycx

We're excited to announce our partnership with Future Pharma EU 2026!Join 140+ pharma marketing, commercial & sales lead...
09/22/2026

We're excited to announce our partnership with Future Pharma EU 2026!

Join 140+ pharma marketing, commercial & sales leaders in Amsterdam this October for two days of real talk, not slide decks. Use code LSVFP10 for 10% off your pass.

Details in the link below: https://tinyurl.com/bdh3nycx

Definium L*D Medication Scores Another Major Anxiety Trial WinAnother positive clinical milestone for Definium’s L*D-bas...
09/16/2026

Definium L*D Medication Scores Another Major Anxiety Trial Win

Another positive clinical milestone for Definium’s L*D-based medication—marking 3 successful anxiety studies out of 3.

This latest result adds to the growing interest in psychedelic-inspired therapies and their potential role in addressing mental health conditions such as anxiety.

Why it matters: Consistent results across multiple studies can strengthen confidence in a drug candidate’s clinical potential and support the path toward further development.

As psychedelic medicine continues to evolve, strong clinical data will be critical in determining which approaches can translate into meaningful patient outcomes.

Read the full story: Link in comment.

*D

FDA Halts Enrollment in Critical Epilepsy Drug TrialsA major setback for Biogen’s epilepsy medication program as the FDA...
09/15/2026

FDA Halts Enrollment in Critical Epilepsy Drug Trials

A major setback for Biogen’s epilepsy medication program as the FDA has halted enrollment in critical clinical trials—adding another challenge for the company and raising questions about the future of the treatment.

For patients, researchers, and the biotech industry, developments like this highlight the complexity of bringing innovative therapies from clinical trials to the market.

Clinical trial setbacks can have significant implications for:

• Patient access to potential new treatments
• Drug development timelines
• Investor confidence
• The broader epilepsy treatment landscape

Stay informed on the latest developments in healthcare, biotechnology, and medical research.

Read the full story: Link in comment.

Matt is responsible for the development and ex*****on of Organon’s financial strategy. He is focused on driving profitab...
09/11/2026

Matt is responsible for the development and ex*****on of Organon’s financial strategy. He is focused on driving profitability and shareholder value and ensuring the highest standard of financial integrity for Organon so it can reach its vision of becoming a leading women’s health company.

Over his career, Matt has served in several public companies as the CFO and in related roles. Before joining Organon, he was the Executive Vice President and CFO at Allergan plc, and Catalent, Inc. Previously, he held finance and leadership positions at Escala Group and GenTek. He has also served in corporate development and other roles in the chemical and banking industries.

Matt is a CFA® Charterholder. Since 2020, he has served on the board of directors of Certara, Inc., a public company provider of software and consulting services to the life sciences industry, and previously was a board member of Multicolor Corporation, a label solutions provider.

Matt has an M.B.A. and B.S. in chemical engineering from Cornell University.

For any concerns, please reach out via direct message.

Ziihera Delivers a Second Survival Win in Advanced HER2-Positive Stomach CancerAnother important development in the figh...
09/08/2026

Ziihera Delivers a Second Survival Win in Advanced HER2-Positive Stomach Cancer

Another important development in the fight against HER2-positive gastric cancer.

Ziihera (zanidatamab) has delivered a second positive survival outcome in an advanced stomach cancer trial, highlighting the potential of targeted therapies to improve outcomes for patients with difficult-to-treat disease.

Why it matters:

• Continued progress in HER2-targeted treatment
• Encouraging survival data in advanced disease
• Another step toward expanding treatment options for patients
• Reinforces the importance of precision medicine in oncology

As clinical research continues to evolve, advances like these offer renewed hope for patients and healthcare professionals working toward better cancer outcomes.

Read the full story: Link in comment.

Clinical research is entering a new era where synthetic data can help researchers overcome one of the biggest challenges...
09/08/2026

Clinical research is entering a new era where synthetic data can help researchers overcome one of the biggest challenges in healthcare: accessing high-quality, representative data while protecting patient privacy.

From accelerating clinical trials to enabling safer AI development, synthetic datasets can:

🔹 Protect sensitive patient information
🔹 Support research when real-world datasets are limited
🔹 Improve diversity and representation in clinical studies
🔹 Enable faster testing and validation of AI models
🔹 Reduce some of the barriers to data sharing and collaboration

The potential is significant—but synthetic data must be carefully validated to ensure it accurately reflects real-world clinical patterns without introducing bias.

The future of clinical research may not be about choosing between real and synthetic data, but learning how to use both responsibly.

Read the full story: Link in comment.

ArsenalBio is restructuring its operations, laying off 99 employees as the biotech shifts its strategic focus toward in ...
09/03/2026

ArsenalBio is restructuring its operations, laying off 99 employees as the biotech shifts its strategic focus toward in vivo CAR-T programs.

The move highlights the rapidly evolving cell therapy landscape, where companies are increasingly exploring approaches that could simplify manufacturing and potentially broaden access to next-generation CAR-T treatments.

Key takeaway: Strategic reprioritization continues to shape the biotech sector as companies balance innovation, resources, and the path toward scalable therapies.

Read the full story: Link in comment.

T

Novartis has reported positive Phase 3 results for Rhapsido (remibrutinib) in patients with relapsing multiple sclerosis...
09/03/2026

Novartis has reported positive Phase 3 results for Rhapsido (remibrutinib) in patients with relapsing multiple sclerosis (RMS).

The findings add to the growing body of research exploring new treatment approaches that could help reduce disease activity and improve outcomes for people living with MS.

Why it matters:

Clinical trial results like these are an important step toward expanding treatment options and addressing the ongoing needs of the MS community.

Read the full story: Link in comment.

Jamie Brannan is Executive Vice President and Chief Commercial Officer at Zoetis, the world’s leading animal health comp...
09/03/2026

Jamie Brannan is Executive Vice President and Chief Commercial Officer at Zoetis, the world’s leading animal health company and a member of the Fortune 500. In this role, he’s responsible for Global Commercial Transformation and Excellence, International Commercial Operations, Global Strategic Accounts, Global Diagnostics, Aquaculture, BioDevices, and Precision Animal Health. As a senior business leader in human and animal health for over a decade, Mr. Brannan has consistently demonstrated strong commercial leadership, excellent financial performance, and a commitment to colleague development and engagement.

Previously, Mr. Brannan served as Executive Vice President and Group President of International Operations, Aquaculture and Global Diagnostics from November 2022 – November 2024, where his exceptional commercial leadership in navigating diverse and complex international market conditions advanced the business significantly. Before that, he served as President, Zoetis International Operations from June 2021 until November 2022. Prior to leading International Operations, Mr. Brannan served as Senior Vice President of Zoetis’ Northern Europe Cluster from October 2016 until June 2021.

Before joining Zoetis, Mr. Brannan served as General Manager at Mölnlycke for UK and Ireland and held roles of increasing responsibility in the Ecolab healthcare division. Prior to beginning his commercial-facing career, he worked as a microbiologist in laboratories in the UK.

Mr. Brannan is the Board Chair of Animal Health Institute, a U.S. association representing companies that develop and produce animal medicines. The group’s focus areas include addressing unmet animal health needs and advancing One Health, innovation, and sustainability in the animal health industry.

Along with a keen focus on business performance and serving customers, Mr. Brannan underlines his leadership style with an emphasis on people – driving colleague engagement and development as well as mental health and well-being programs to support colleagues around the world.

Mr. Brannan holds a bachelor’s degree from Anglia Ruskin University, where he graduated with honors.

For any concerns, please reach out via direct message.

Address

New York, NY

Website

Alerts

Be the first to know and let us send you an email when Life Sciences Voice posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Life Sciences Voice:

Shortcuts

Share

Category